Introduction
Protein C (PC)' is a vitamin K-dependent plasma protein which, in the active form (PCa), exerts anticoagulant activity (1) by degrading factors Va and Vllla (2) . Activation of PC occurs via proteolytic cleavage of the molecule by a complex between thrombin and an endothelial cell cofactor, thrombomodulin (3) .
PCa has been demonstrated to express profibrinolytic activity in vitro and in vivo (4, 5, 6) . Infusion of bovine PCa into dogs resulted in increased levels of plasminogen activator (PA) in blood (4) . Increase of circulating PA has also been observed in dogs following activation of endogenous PC by infusion of low doses ofthrombin (5) . In vitro, the rate ofblood clot lysis induced by tissue PA was markedly enhanced in the presence of PCa (6) . Because of its anticoagulant and profibrinolytic properties, PC may play a primary role in the regulation of hemostasis. Some studies (7) , however, have indicated that species specificity may be an important determinant in the expression of the biological properties of PC.
To eliminate species variability as much as possible and to obtain information which may be more relevant to man, we investigated the profibrinolytic properties of human PC in squirrel monkeys. 1 . Abbreviations used in this paper: APTT, activated partial thromboplastin time; DDAVP, 1 (14) as reported (12) . Blood fibrinolytic activity was also evaluated by measuring the release of '25I-fibrin degradation products from radiolabeled Ci/mg) plus 50 Ml thrombin (25 U/ml) were added. The sample was incubated for 10 min at room temperature and then the clotted blood was freed from the wall of the tube by rimming it with a glass rod. After an additional 30-min incubation at 370C, the clot was removed and transferred into a petri dish containing 20 ml of 20 mM Tris-HCI, 130 mM NaCl buffer, pH 7.4. 10 min later, the buffer was replaced and the clot incubated for a further 10 min. The washed clot was finally added to a 16 X 95-mm polystyrene tube containing 0.6 ml of plasma obtained from another portion of the same blood sample. The radioactivity associated with the washed clot was -60% of the total amount added to the blood. The final sample was incubated at 370C, and at hourly intervals, 10 Ml of plasma were withdrawn for the estimation of '25I-fibrin-split products.
Isolation of vitamin K-dependent plasma proteins and assay ofPC. Blood was collected into 0.4% citrate and 10 mM benzamidine (final concentration). Prothrombin complex was prepared from plasma by barium citrate adsorption, sodium citrate wash, and EDTA elution (8). 5 mM benzamidine was added to the wash and elution steps. The prothrombin complex was dialyzed against 20 mM Tris-HCl buffer, pH 7.4, containing 150 mM NaCI and 0.01% Tween 80. Full activation of PC in the barium citrate plasma eluate was obtained by incubation with thrombin (5 U/ml) for 1 h at 370C. Thrombin was then neutralized by an additional 10-min incubation in the presence of antithrombin III (15 Mg/ml). PCa was measured by both amidolytic (8) and clotting assays. The latter were performed by estimating the prolongation of the APMT ofnormal monkey plasma following addition of 20 Ml ofthrombinactivated barium citrate eluate. An example is illustrated in Fig. 1 . To determine the levels of PCa generated in vivo following T-TM infusion, a barium citrate eluate of monkey plasma was prepared as outlined above. PCa activity in this sample was measured omitting activation with thrombin and was expressed as percent of the activity generated in the preinfusion sample after maximal activation with thrombin in vitro.
Results
Intravenous administration of human PCa to squirrel monkeys (3 ug PCa/ml blood) resulted in prolongation of the APTT without relevant changes in TT and PA activity (Fig. 2) . Platelet count, FV, and fibrinogen levels were also unchanged. In vitro, the addition ofan equivalent amount ofhuman PCa to monkey plasma induced a comparable prolongation of APTT without affecting the TT. No anticoagulant activity was expressed by unactivated PC (not shown).
The fibrinolytic response to endogenous PCa was investigated by infusing the squirrel monkeys with T-TM. Infusion of T-TM over 30 min at a rate of 2.9 ,ug/kg body weight per min (corresponding to 2 U of bound thrombin/kg per min) induced a marked prolongation of the APTT without affecting plasma TT (Fig. 2) .
Blood anticoagulation was caused by PC activation as indicated by the following findings (Fig. 3) . Plasma (Fig. 4) . In addition, it exhibited amidolytic activity towards the synthetic substrate S-2266 and was not neutralized by antithrombin III.
By clotting and amidolytic assays, it was found that peak levels of PCa activity recovered from postinfusion plasma amounted to between 20 and 30% of the total PC present in preinfusion samples. Despite this high level of PCa, T-TM infusion was not associated with an increase of circulating PA (Fig. 2) . Lack of fibrinolytic response was also confirmed by measuring '251-fibrin degradation products released from radiolabeled clots (Fig. 5) . No fibrinogen levels were observed during the infusion. In two additional experiments, monkeys were infused with a complex of human thrombin and monkey thrombomodulin. In this case, also, generation ofPCa (18-29% oftotal) did not lead to increased levels of PA in blood (between 80 and 110% of preinfusion value). To exclude the theoretical possibility that circulating T-TM complex was interfering with the release of PA, we measured the fibrinolytic response to 1-desamino 8-D arginine vasopressin (DDAVP) in monkeys that had received an infusion of T-TM. DDAVP (10 ,ug/kg body weight) was injected immediately after the end of T-TM infusion and blood samples were taken 2 min later for PA assay. In two separate experiments, DDAVP induced a marked increase of blood PA activity (330 and 395% of pre(T-TM)-infusion value). The addition to plasma euglobulins of rabbit Ig (5 ;tg/ml final concentration) directed against human tissue PA resulted in the inhibition of >80% of the activity present in post-DDAVP samples and inhibition of 30-45% of the activity present in pre-and post-T-TM samples.
In all instances, <5% ofthe activity was quenched by comparable amounts of rabbit anti-human urokinase Ig or nonimmune rabbit Ig.
Infusion of thrombomodulin alone (0.57 jg/kg body weight per min, a dose comparable with the free thrombomodulin present in the T-TM complex infused in the above mentioned experiments) did not noticeably affect any of the parameters studied.
In our experiments, infusion of low doses of thrombin (1 or 2 U/kg body weight per min over 20 or 60 min) did not elicit a selective prolongation of the APTT as a result of PC activation and was not associated with an increase of PA activity in blood.
The following experiments were carried out to assess whether a blood component which might be involved in the PCa-induced release of PA could be missing in the monkey. Human blood was incubated with PCa (6 ,gg/ml) for 10 min at 370C. 5 ml of plasma obtained from this latter sample were infused (1 ml/min) in the squirrel monkey and blood aliquots were withdrawn at predetermined intervals for PA assay. Fig. 6 shows that no changes in plasma PA activity occurred over the period of the experiment.
Discussion
Infusion of human PCa into squirrel monkeys at a dose of 3 ,ug/ml blood did not result in an increase of circulating PA activity. The lack of fibrinolytic response did not appear to be due to species specificity because the anticoagulant activity of human PC was strongly expressed in the monkey. Furthermore, no PA release was observed following activation of endogenous PC by T-TM infusion. T-TM complex has been demonstrated to be a very potent activator of PC devoid ofclotting and plateletactivating activities (3, 10, 15, 16) The possibility that the squirrel monkey is a poor responder to PA releasing agents is excluded. Previous investigations by our laboratory (17) have indeed shown that infusion of known stimulators of PA release, such as vasopressin or DDAVP, induce a marked fibrinolytic response in the squirrel monkey (up to threefold increase in the plasma levels of PA). Furthermore, we demonstrated that the increase of circulating PA is mainly due to the release of tissue-type PA. Finally, evidence was provided that the presence in the circulation of soluble T-TM, which at least in physiological conditions is not a circulating complex (3), does not affect the fibrinolytic potential of the animals.
Bovine PCa has been demonstrated to induce PA release in dogs via a second messenger present in blood (4) . It is possible that, in the squirrel monkey, this second messenger is missing or does not interact with PCa. If this is so, the question arises as to whether, in humans, PCa is capable of inducing generation of a PA-releasing factor in blood. In our experiments, no fibrinolytic response was observed in monkey following infusion of plasma obtained from PCa-stimulated whole human blood. Such evidence is very suggestive but not totally conclusive to exclude the existence in human blood of a second messenger for PCa-induced release of PA.
In conclusion, our findings indicate that PCa does not have profibrinolytic properties in squirrel monkeys, and thus, they raise some questions on the role ofthis enzyme in the regulation of PA release in man.
